Evaluation of a Leishmania hypothetical protein administered as DNA vaccine or recombinant protein against Leishmania infantum infection and its immunogenicity in humans

Ribeiro, Patrícia A.F.; Dias, Daniel Lucas Santos; Lage, Daniela P.; Costa, Lourena E.; Martins, Vívian T.; Tavares, Grasiele S.V.; Mendonça, Débora V.C.; Lima, Mariana P.; Oliveira, Jamil S.; Steiner, Bethina T.; Machado-de-Ávila, Ricardo Andrez; Roatt, Bruno Mendes; Chávez-Fumagalli, Miguel Á.; Menezes‐Souza, Daniel; Duarte, Mariana C.; Teixeira, Antônio Lúcio; Coelho, Eduardo Antônio Ferraz

doi:10.1016/j.cellimm.2018.05.009

Cited by 11 publications

(4 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These proteins were potentially utilized as drug targets or vaccine candidates (Sinha et al 2017 ). Since some HPs substantially affect the pathogenesis of leishmaniasis, some of these proteins are used in a recombinant vaccine against infection with Leishmania parasites (Duarte et al 2017 ; Martins et al 2016 ; Ribeiro et al 2018 ). Besides, the membrane and secretory proteins play a crucial role in stimulating a host-specific immune response (Khatoon et al 2019 ).…”

Section: Introductionmentioning

confidence: 99%

Immunoinformatics Approach to Design a Novel Subunit Vaccine Against Visceral Leishmaniasis

Lari

Biabangard

2021

Int J Pept Res Ther

View full text Add to dashboard Cite

Visceral leishmaniasis (VL) infection is mostly caused by Leishmania donovani and affects countries worldwide. Despite the need for a safe and effective vaccine against leishmaniasis due to the increased drug resistance, however, no vaccine has yet been licensed for clinical use. This study revolves around the immunoinformatics approach to design a multi-epitope vaccine against VL infection. In this case, the proteome of L. donovani has been investigated, and three host non-homologous and antigenic extracellular secretory proteins have been identified as potential vaccine candidates with low transmembrane helices (≤ 1). The multi-epitope subunit vaccine construct consists of T-cell (cytotoxic T-lymphocyte (CTL) and helper T-lymphocyte (HTL)) epitopes accompanied by appropriate adjuvant and linkers. A 372-amino acid vaccine construct has been established with specific characteristics, such as soluble, stable, antigenic, non-allergenic, non-toxic, and non-host homologous. Besides, the tertiary structure of the designed vaccine was modeled and validated. Also, the stability and affinity of the vaccine- TLR4 complex were confirmed by using molecular docking and molecular dynamics (MD) simulation. In addition, in silico immunization assay showed the efficiency of this candidate vaccine to stimulate an effective immune response. Furthermore, the refined vaccine was optimized and cloned in the pET28a (+) vector, and its successful expression was confirmed virtually. However, the experimental validation is required to verify the multi-epitope vaccine efficacy against VL infection.

show abstract

Section: Introductionmentioning

confidence: 99%

Immunoinformatics Approach to Design a Novel Subunit Vaccine Against Visceral Leishmaniasis

Lari

Biabangard

2021

Int J Pept Res Ther

View full text Add to dashboard Cite

show abstract

“…These include a Th1 stimulatory protein from a clinical isolate of L. donovani [11,13]. Some hypothetical proteins have been evaluated as a DNA vaccine or recombinant protein vaccine against Leishmania infection [14,15]. The absence of detailed information on the properties of HyPs reveals our limited understanding of the parasite survival in the host during natural infections.…”

Section: Introductionmentioning

confidence: 99%

Design of a multi-epitope subunit vaccine for immune-protection against Leishmania parasite

Yadav

Prakash

Shukla

et al. 2020

Pathogens and Global Health

View full text Add to dashboard Cite

Visceral Leishmaniasis (VL) is an insect-borne neglected disease caused by the protozoan parasite Leishmania donovani. In the absence of a commercial vaccine against VL, chemotherapy is currently the only option used for the treatment of VL. Vaccination has been considered as the most effective and powerful tool for complete eradication and control of infectious diseases. In this study, we aimed to design a peptide-based vaccine against L. donovani using immunobioinformatic tools. We identified 6 HTL, 18 CTL, and 25 B-cell epitopes from three hypothetical membrane proteins of L. donovani. All these epitopes were used to make a vaccine construct along with linkers. An adjuvant was also added at the N-terminal to enhance its immunogenicity. After that, we checked the quality of this vaccine construct and found that it is nontoxic, nonallergic, and thermally stable. A 3D structure of the vaccine construct was also generated by homology modeling to evaluate its interaction with innate immune receptors (TLR). Molecular docking was performed, which confirmed its binding with a toll-like receptor-2 (TLR-2). The stability of vaccine-TLR-2 complex and underlying interactions were evaluated using molecular dynamic simulation. Lastly, we carried out in silico cloning to check the expression of the final designed vaccine. The designed vaccine construct needs further experimental and clinical investigations to develop it as a safe and effective vaccine against VL infection.

show abstract

“…An intensive research has been carried out to demonstrate the safety of the polymer and its ability to activate wound healing and tissue repair. Furthermore, CS is generally recognized as safe [8] by the FDA for wound applications [9] and it has a well-characterized biocompatibility profile, which makes it a promising biopolymer for use in implanted devices and for drug delivery [10,11]. In fact, the development of commercial products in the form of wound dressings constitutes one of the most consolidated applications of this polymer in clinical practice ( Table 1) [12][13][14].…”

Section: Introductionmentioning

confidence: 99%

Chitosan Applications on Pharmaceutical Sciences: A Review

Villegas

Cid

Romero

et al. 2019

DDL

View full text Add to dashboard Cite

Background: Chitosan (CS) is a biomaterial derived from chitin, known for its excellent biological properties. One of the most interesting features of CS is its potential for chemical derivatization, which makes it a versatile material and allows to expand its applications. In the last years, the interest on this polymer and its pharmaceutical applications has notably increased. This biopolymer is being widely studied for its interesting properties, such as bioadhesion, antimicrobial activity, biocompatibility, and biodegradability. Other promising properties of CS include its modulation of immunological response, hemostasis, and wound and bone healing activity. Objective: In this work, a critical review is performed covering its conventional and novel applications, specially focused on pharmaceutical area, providing a clear picture of the current state of art to serve as a basis to direct future research in this field. Conclusion: Despite all the qualities of this polymer, there are only few CS-based products in the market, so it is a priority to enhance the research to develop new technologies and CS-based systems to enforce this biopolymer in the industry.

show abstract

Evaluation of a Leishmania hypothetical protein administered as DNA vaccine or recombinant protein against Leishmania infantum infection and its immunogenicity in humans

Cited by 11 publications

References 52 publications

Immunoinformatics Approach to Design a Novel Subunit Vaccine Against Visceral Leishmaniasis

Immunoinformatics Approach to Design a Novel Subunit Vaccine Against Visceral Leishmaniasis

Design of a multi-epitope subunit vaccine for immune-protection against Leishmania parasite

Chitosan Applications on Pharmaceutical Sciences: A Review

Contact Info

Product

Resources

About